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Abstract
Background: Modulation of neurogenesis that acts as an endogenous repair mechanism would have a significant impact on
future therapeutic strategies for Parkinson’s disease (PD). Several studies demonstrated dopaminergic modulation of
neurogenesis in the subventricular zone (SVZ) of the adult brain. Levodopa, the gold standard therapy for PD, causes an
increase in homocysteine levels that induces neuronal death via N-methyl-D-aspartate (NMDA) receptor. The present study
investigated whether elevated homocysteine by levodopa treatment in a parkinsonian model would modulate
neurogenesis via NMDA receptor signal cascade and compared the effect of levodopa and pramipexol (PPX) on
neurogenic activity.
Methodology/Principal Findings: Neurogenesis was assessed in vitro using neural progenitor cells (NPCs) isolated from the
SVZ and in vivo with the BrdU-injected animal model of PD using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Modulation
of homocysteine levels was evaluated using co-cultures of NPCs and astrocytes and PD animals. Immunochemical and
Western blot analyses were used to measure neurogenesis and determine the cell death signaling. Levodopa treatment
increased release of homocysteine on astrocytes culture media as well as in plasma and brain of PD animals. Increased
homocysteine by levodopa led to increased apoptosis of NPCs through the NMDA receptor-dependent the extracellular
signal-regulated kinase (ERK) signaling pathways. The administration of a NMDA antagonist significantly attenuated
apoptotic cell death in levodopa-treated NPCs and markedly increased the number of BrdU-positive cells in the SVZ of
levodopa-treated PD animals. Comparative analysis revealed that PPX treatment significantly increased the number of NPCs
and BrdU-positive cells in the SVZ of PD animals compared to levodopa treatment. Our present study demonstrated that
increased homocysteine by levodopa has a detrimental effect on neurogenesis through NMDA receptor-mediated ERK
signaling pathway.
Conclusions/Significance: Modulation of levodopa-induced elevated homocysteine by NMDA antagonist or dopamine
agonist has a clinical relevance for PD treatment in terms of adult neurogenesis.
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Introduction
Recent studies have demonstrated that the adult mammalian
brain has the potential to generate new neurons and to incorporate
them into brain areas affected by a disease process. The
neurogenesis that occurs in the subventricular zone (SVZ) and
the subgranular zone of the dentate gyrus may act as an
endogenous repair mechanism [1]. Several factors including
neurotransmitters, growth factor, and disease states have been
suggested to modulate neurogenesis [2]. Thus, modulation of
endogenous neurogenesis would have a significant impact on
future therapeutic strategies for neurodegenerative diseases, such
as Alzheimer’s disease and Parkinson’s disease (PD). Growing
evidence indicates that neurogenesis in the SVZ and hippocampus
is decreased significantly in patients with PD and in animal model
of PD [3]. Other findings have suggested that neurochemical
deficit of dopamine and direct a-synuclein accumulation in neural
precursor cells of the SVZ may influence neurogenic activity [3,4].
The neural precursor cells in the SVZ express dopamine receptors,
and several animal data suggest that dopamine-enhancing drugs
increase neurogenesis in the SVZ [5,6].
Levodopa treatment is the gold standard therapy for patients
with PD, with its ability to control motor symptoms, improve
quality of life, and prolong a patient’s life-expectancy. Levodopa
therapy, however, causes an increase in serum homocysteine level
as the drug is metabolized via catechol O-methyltransferase [7].
Hyperhomocysteinemia, the accumulation of homocysteine in the
circulation, has received considerable attention in the last decade
with respect to a number of disease states, since hyperhomocys-
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teinemia is regarded as an independent risk factor for vascular
diseases and cognitive impairments in elderly people [8]. Indeed,
some reports have demonstrated that hyperhomocysteinemia in
PD might be associated with increased prevalence of coronary
artery disease, hypertrophy of carotid artery, peripheral neurode-
generation, and increased cerebrovascular resistance [9–12].
Although cell death mechanisms by elevated homocysteine are
not clear; homocysteine- N-methyl-d-aspartate (NMDA) receptor
stimulation seems to play a key role in inducing neuronal damage.
Recent in vitro studies have shown that elevated homocysteine
levels induced oxidative stress through NMDA receptor-mediated
neuronal nitric oxide synthase activation and free radical
formation, thus causing a significant increase in neuronal cell
death [13,14]. Furthermore, Rabaneda et al. [15] recently
demonstrated in vitro and in vivo evidence suggesting that
homocysteine inhibits the proliferation of neural progenitor cells
(NPCs) in the SVZ by impairing basic fibroblast growth factor-
induced proliferation. To date, no study has investigated a direct
cause-effect association between levodopa-induced homocysteine
elevation and neurogenic activity in the parkinsonian model. In
the present study, we performed in vitro and in vivo experiments
to investigate whether elevated homocysteine by levodopa would
modulate neurogenesis via the NMDA receptor signaling cascade.
Additionally, we performed comparative analysis of neurogenic
activity between levodopa and pramipexol (PPX), a dopamine
agonist.
Materials and Methods
Animals and Drugs Administration
All procedures of this animal research were performed in
accordance with the Laboratory Animals Welfare Act, the Guide
for the Care and Use of Laboratory Animals and the Guidelines
and Policies for Rodent experiment provided by the IACUC
(Institutional Animal Care and Use Committee) in the Yonsei
University Health System. Male C57BL/6J mice (5 weeks old)
were acclimated in a climate-controlled room with a constant 12 h
light/dark cycle (12 h on, 12 h off) for a week prior to the
initiation of drug administration. At 6 weeks of age, the mice
received subchronic injections of 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine (MPTP) freshly dissolved in normal saline (25 mg/
kg/day as the free base in normal saline by intraperitoneal
injection (i.p).; Sigma, St. Louis, MO, USA) [16] or vehicle
(normal saline, 0.1 ml/10 mg, i.p) for 5 days. On day 8 after the
first MTPT injection, the mice were randomly divided into six
groups (n = 4–5) and treated daily with levodopa (SinemetH,
carbidopa/levodopa, 25/100 mg. MSD, USA), PPX (1 mg,
Boehringer-Ingelheim, Germany), or normal saline for 4 weeks,
as follows: Group 1, control group; Group 2, normal saline-treated
mice (normal saline, 0.1 ml/10 mg, i.p; MPTP-only treatment
group); Group 3, levodopa-treated mice (20 mg/kg, twice daily,
i.p; MPTP+levodopa treatment group) [17]; Group 4, levodopa
and the noncompetitive NMDA-receptor antagonist dizocilpine
(MK-801)-treated mice (10 mg/kg, once daily, ip; MPTP+levo-
dopa and MK-801treatment group) [18]; Group 5, PPX-treated
mice (1 mg/kg, twice daily, i.p; MPTP+PPX treatment group)
[19]; and Group 6, PPX and MK-801-treated mice (MPTP+PPX
and MK-801 treatment group). On day 28 after the first
administration of levodopa, PPX, or normal saline, all animals
were assigned to a BrdU injection regime following a modified
protocol described by Kralic et al [20]. BrdU (Sigma, St. Louis,
MO, USA) was dissolved in phosphate-buffered saline (PBS) and
administered i.p once daily on five subsequent days at a
concentration of 50 mg/kg. The in vivo study design is illustrated
in Figure S1.
NPCs and Astrocyte Culture
A parasagittal section was taken from the medial surface of each
hemisphere of Sprague-Dawley (SD) rat embryos, and a wedge of
tissue was microdissected from the portion of the lateral ventricle
that included the anterior part of the SVZ [21]. The isolated NPCs
were expanded in Dulbecco’s modified Eagle’s medium and
Ham’s F-12 Nutrient Mixture (DMEM/F-12 mixture, 1:1)
complete media supplemented with epidermal growth factor and
basic fibroblast growth factor (20 ng/mL each; both from
PromoCell, Heidelberg, Germany) [22]. In the experiments,
NPCs were plated on 6-well plate at a density of 16104/cm2
(Corning, NY, USA). Astrocytes were cultured from the cerebral
cortices of 1-day-old SD rats. The dissociated cells were plated in
T75 flasks. On day 14 after preparation, cells were shaken
vigorously at least 3 times to detach microglia cells from astrocytes
layer and removed. In the experiment, cells were plated in a
transwell insert at a density of 56103/cm2 (Corning, NY, USA).
The astrocytes were treated with varying doses of levodopa and
PPX to identify a dose that did not induce cell death. For each
condition, the viability of astrocytes decreased in a dose-dependent
manner. Additionally, NPCs were treated with different doses of
MK-801 to identify a dose that did not induce cell death (Figure
S2) and SCH-23390, a dopamine 1 receptor antagonist, to identify
that did not induce ERK activation (Figure S3). Accordingly, all
experiments were performed using 200 mM levodopa, 1 mM PPX,
10 mM MK-801 and 50 nM SCH-23390 [23].
Co-Cultures of NPCs and Astrocytes Treated with
Levodopa or PPX
The effects of homocysteine were tested in astrocytes and NPCs
that were co-cultured with no cell contact. The astrocytes treated
with levodopa or PPX were maintained on a Costar transwell
insert (Corning Incorporated) and the NPCs were maintained on
the bottom of a 6-well plate in a humidified incubator at 37uC and
5% CO2 for 24 h or 72 h. The NPCs were then collected for
assay. All experiments were replicated 3 times.
Preparation of Plasma and Brain Samples
Blood samples were collected into EDTA-containing tubes (BD
Diagnostic Systems, Sparks, MD, USA), and plasma and blood
cells were separated by centrifugation (20006g for 20 min). The
isolated mouse brain and plasma were rapidly frozen and stored at
270uC until analyzed. For immunochemical analysis, all mice
were deeply anesthetized with chloral hydrate (0.4 g/kg, i.p.) and
then perfused with 4% paraformaldehyde in 0.1 M phosphate
buffer (PB; pH 7.4). The brains were then sectioned on a sliding
microtome to obtain 30-mm-thick coronal sections. All sections
were stored in tissue stock solution (30% glycerol, 30% ethylene
glycol, 30% 3rd D.W., 10% 0.2 M PB; pH 7.2; Sigma) at 4uC
until required. For gas chromatography-mass spectrometry (GC-
MS), the animals were sacrificed and the brains were rapidly
frozen at 270uC.
Measurements of Homocysteine
Hemi- brain tissues were homogenized and centrifuged
(140006g for 20 min, 4uC). The supernatant was transferred to
a fresh tube for the homocysteine assay using gas chromatography-
mass spectrometry (GC-MS). GC with selected ion-monitoring
MS (GC-SIM-MS) runs was performed in triplicate. The mass
range scanned was 50–800 U at a rate of 0.42 scan/s.
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Immunohistochemistry and Immunocytochemistry
The brain sections and co-cultured NPCs were rinsed twice in
PBS and stained using specific antibodies. The primary antibodies
were used as follows: mouse anti-OX-42 (1:200 for immunocyto-
chemistry; Serotec, Raleigh, NC, USA), mouse anti-GFAP (1:200
for immunocytochemistry; Abcam, Cambridge, UK), rabbit anti-
nestin (1:200 for immunocytochemistry, Chemicon, Billerica, MA,
USA), mouse anti-Ki67 (1:200 for immunocytochemistry, Chemi-
con, Billerica, MA, USA), rabbit anti-NMDA2A receptor and
NMDA2B receptor (1:200 for immunocyto- and immunohisto-
chemistry, Chemicon, Billerica, MA, USA), mouse anti-BrdU
(1:200 for immunohistochemistry, Roche, IN, USA). The
antibodies were detected with 0.05% diaminobenzidine (DAB,
Vector Laboratories, Burlingame, CA, USA) and 0.03% H2O2.
Immunofluorescence labeling was carried out by incubating the
cells in goat anti-mouse IgG and goat anti-rabbit IgG (both
AlexaFluor-488, green and Alexa Fluor-594, red) secondary
antibodies (Chemicon Chemicon, Billerica, MA, USA). The cell
nuclei were counterstained with 49,6-diamidino-2-phenylindole
(DAPI; 1:2000 dilution, Molecular Probes, Invitrogen, Carlsbad,
CA, USA). The brain tissue was dried and stained with Mayer’s
hematoxylin (Muto Pure Chemicals Ltd., Tokyo, Japan). The
immunostained cells were analyzed using bright-field microscopy
and viewed under a confocal laser scanning microscope (Olympus,
Tokyo, Japan).
Stereological Cell Counts
Unbiased stereological estimations of the total number of the
stained cells in the SVZ were made using an optical fractionator,
as previously described with some modifications [24]. This
sampling technique is not affected by tissue volume changes and
does not require reference volume determinations. The sections
used for counting covered SVZ. This generally yielded 8–12
sections in a series. Sampling was performed with the Olympus
C.A.S.T.-Grid system (Olympus Denmark A/S, Denmark), using
an Olympus BX51 microscope, connected to the stage and feeding
the computer with the distance information in the z-axis. A
counting frame (55%, 53, 1281 mm2) was placed randomly on the
first counting area and systematically moved though all counting
areas until the entire delineated area was sampled. Actual counting
was performed using a x100 oil objective. Guard volumes (4 mm
from the top and 4–6 mm from the bottom of the section) were
excluded from both surfaces to avoid the problem of a lost cap,
and only the profiles that came into focus within the counting
volume (with a depth of 10 mm) were counted. The total number
of stained cells was calculated according to the optical fractionator
formula [25].
Total RNA Extraction and Reverse Transcriptive PCR (RT-
PCR)
Total RNA was extracted from the NPCs using Trizol reagent
(Invitrogen, Carlsbad, CA, USA) in accordance with the
manufacturer’s protocol. An equal amount of RNA (approximate-
ly 1 mg) in each experiment was reverse transcribed using an
amfiRivert cDNA Synthesis Premix (GenDEPOT, Barker, TX,
USA). Subsequently, 2 ml of cDNA was used as a template for RT-
PCR analysis in amfiRivert 1-Step RT-PCR Kit. (GenDEPOT,
Barker, TX, USA). The PCR reaction was performed using
10 pmol each of the primers for NMDA receptor 1 (NR1; forward
59-CTG CAA CCC TCA CTT TTG AG-39, reverse 59-TGC
AAA AGC CAG CTG CAT CT-39), NMAD 2A receptor (NR2A;
forward 59- GAC GGT CTT GGG ATC TTA AC-39, reverse 59-
TGA CCA TGA ATT GGT GCA GG-39), NMAD 2B receptor
(NR2B; forward 59- CAA GAA CAT GGC CAA CCT GT-39,
reverse 59- GGT ACA CAT TGC TGT CCT TC-39), NMAD 2C
receptor (NR2C; forward 59- TGG AAA CTT CGA CAC TCG
GT-39, reverse 59- TCC AAA GAG CTG CTC ACG TC-39)
[26]. After an initial denaturation at 94uC for 5 min, 30 cycles of
PCR were performed, consisting of denaturation (30 s, 94uC),
annealing (1 min, 58uC [NMDA receptor 1], 55uC [NMDA
receptor 2A, NMDA receptor 2B], 57uC [NMDA receptor 2C]),
extension (1 min, 72uC) followed by a final extension (10 min,
72uC). The PCR products were separated by electrophoresis on
2% agarose gel and stained with ethidium bromide. Gels were
examined under UV illumination.
Flow Cytometric Measurement of Cell Death Using
Annexin-V/PI
Flow cytometric analysis was performed to evaluate the extent
of apoptotic and necrotic cells. Co-cultured NPCs were harvested
and stained with Annexin/PI using kit (BD, San diego, CA, USA).
We counted only Annexin V-positive cells in the right-lower
quadrant (apoptotic cells). Samples were immediately kept on ice
and analyzed on FACS. Data was acquired and analyzed using
Winmdi software (http://www.cyto.purdue.edu/flowcyt/
software/Winmdi.htm). Acquisition gates were wet using the
forward and side light scatter of the cells and a minimum of 10,000
events were collected for each sample.
Caspase-3 Activity Assay
Caspase-3 activity was measured by monitoring the proteolysis
of corresponding colorimetric substrates using a caspase-3 activity
assay kit (Chemicon, Billerica, MA, USA). Co-cultured NPCs were
collected and washed in ice-cold PBS (pH 7.0) and subsequently
lysed in 16 lysis buffer for 10 min in ice; the lysates were clarified
by centrifugation at 16,0006g for 10 min. After centrifugation for
10 min, cytosolic extracts of NPCs were transferred to a fresh tube
and put on ice. Then 30 mg of the caspase-3-specific colorimetric
substrate acetyl-Asp-Glu-Val-Asp-7-p-nitroaniline (Ac-DEVD-p
NA) was added to the cytosolic extracts. The extracts were
incubated for 1 h at 37uC. The release of DEVD-p NA was
quantified at 405 nm using an enzyme-linked immunosorbent
assay (ELISA) plate reader.
Western Blot Analysis
For western blotting, co-cultured NPC were harvested and
extracted using lysis buffer containing protease inhibitor (iNtRON
Biotechnology, SeongNam, S. Korea). Briefly, 50 mg of protein
were separated using SDS-gel electrophoresis and transferred to
nitrocellulose membrane (Amersham, Piscataway, NJ, USA). The
membranes were blocked in non-fat milk. Membranes were
probed with 1:1000 dilutions of the following primary antibodies:
rabbit polyclonal the extraceullar signal-regulated kinase (ERK)1/
2 and rabbit polyclonal phospho-ERK1/2 (Cell Signaling,
Danvers, MA, USA). As a secondary antibody, a 1:2000 dilution
of horseradish peroxidase-conjugated goat anti-rabbit antibody
(Zymed Laboratories, San Francisco, CA, USA) was used.
Antigen-antibody complexes were visualized with a chemilumi-
nescence system (Amersham, Piscataway, NJ, USA), followed by
exposure to X-ray film (Kodak X-OMAT, Rochester, NY, USA).
For semiquantitative analysis, the densities of the immunoblot
bands were measured by computer imaging (Image J; NIH,
Bethesda, MD, USA). All proteins were normalized with actin.
Neurogenesis in Parkinson’s Disease
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Statistical Analysis
The group means were compared using the Mann-Whitney U-
test for pairs and the Kruskal-Wallis analysis for multiple groups.
P-values less than 0.05 were considered statistically significant.
Statistical analyses were performed using commercially available
software (version 12.0; SPSS Inc., Chicago, IL).
Results
Phenotype and Proliferative Capacity of the Cultured
NPCs
The phenotypic properties of the NPCs were determined using
nestin, the neural stem cell marker, to reveal cells expressing a
neuronal phenotype, whereas GFAP (an astrocyte marker) and
OX-42 (a microglia marker) were applied to reveal the presence of
glial cells. No GFAP-positive or OX-42-positive cells were
observed in the cultured NPCs (Fig. 1A and B), and most of the
NPCs were nestin-positive (Fig. 1C). Additionally, the NPCs were
immunostained with Ki67 (Fig 1F, G, H), a proliferation marker
and MAP 2 (Fig 1I, J, K), a neuronal marker.
mRNA Expression and Immunodetection of NMDA
Receptor Subunits in Cultured NPCs
Immunocytochemistry revealed that NPCs expressed NMDA
receptor NR2A and NR2B subunits (Fig. 2A and B). These results
were confirmed by RT-PCR showing total RNA isolated from
NPCs expressing detectable NR1, NR2A, NR2B, and NR2C
(Fig. 2C).
Levodopa Treatment Leads to Increased Release of
Homocysteine on Astrocyte Culture Media
The astrocyte culture media was treated with levodopa to
determine its effect on homocysteine levels. The extracellular
concentration of homocysteine increased linearly in a time-
dependent manner during incubation with levodopa and reached
its highest level at 72 h after levodopa treatment. Levodopa-
induced homocysteine release was dependent on the number of
astrocytes with the maximum level in the highest dose of levodopa
(Fig. 3A and B). Homocysteine was not detectable in astrocyte
culture media after PPX treatment (Fig. 3A and B) and in
levodopa-treated NPC culture media without astrocyte (data not
shown).
Levodopa Treatment Induces Apoptotic Cell Death in
NPCs
The NPCs were treated with different doses of homocysteine to
evaluate the direct effects of homocysteine on the viability of NPCs
measured by trypan blue cell counting. Homocysteine treatment
decreased the viability of NPCs in a dose-dependent manner
(Figure S3 A). Next, NPCs were co-cultured with levodopa- or
PPX-treated astrocytes for 24 h and 72 h, respectively, to
determine whether levodopa stimulated an increase in homocys-
teine-activated apoptosis. Caspase-3 activity significantly increased
in a time-dependent manner in levodopa-treated NPCs and was
significantly higher than that in the control or PPX-treated NPCs
at 72 h (Fig.4A). Furthermore, the flow cytometric assay using
Annexin V/PI revealed that Annexin-V-positive cells, a cluster in
the right-lower quadrant, had significantly increased in the
levodopa-treated NPCs compared to the control and PPX-treated
NPCs (Fig. 4B). A quantitative analysis performed using the flow
cytograms revealed a significant increase in apoptotic cell death in
the levodopa-treated NPCs compared to that in the control and
PPX-treated NPCs (Fig. 4C). NPC viability had significantly
decreased in the levodopa-treated cells as compared to that in the
control and PPX-treated cells (Fig. 4D). MK-801, a NMDA
antagonist, significantly decreased caspase-3 activity, the number
of Annexin-V-positive cells, and cell death in levodopa-treated
NPCs (Fig. 4B, C, D), whereas MK-801 had no significant effect
on apoptotic cell death in PPX-treated NPCs (Fig. 4B, C, D).
Effects of Levodopa Treatment on the Regulation of ERK
Signaling
ERK signaling was assessed by western blot analysis because
homocysteine, as agonist of NMDA receptor, can lead to the
phosphorylation and subsequent activation of ERK signaling in
neurons. Direct treatment of homocysteine in the NPCs increased
the expression of phosphorylated ERK in a dose-dependent
manner but the expression of phosphorylated ERK was decreased
in presence NMDA antagonist, MK-801 (Figure S3 B and C).
Then, NPCs were co-cultured with levodopa or PPX-treated
astrocytes for 72 h to investigate whether increased levels of
homocysteine modulated regulation of ERK signaling pathways
through the NMDA receptor. The phosphorylated form of ERK
was significantly higher in levodopa-treated NPCs compared to
controls (Fig. 5A and B). However, the expression of phosphor-
ylated ERK was attenuated in levodopa-treated NPCs that
received MK-801 treatment compared to the levodopa-only
NPCs (Fig. 5A and B). To evaluate that ERK is not induced by
D1 receptor simulation, the NPCs co-cultured with levodopa
treated- astrocytes were treated with 50 nM D1receptor antago-
nist (SCH-23390) for 72 h. D1 receptor antagonist treatment did
not decrease the expression of phosphorylated ERK, suggesting
that ERK activation is not mediated via D1 receptor on the NPC
(Fig S3 D). The expression of phosphorylated ERK did not
significantly change in PPX-treated NPCs compared to the
controls (Fig. 5A and B).
Levodopa Treatment Leads to Increased Homocysteine
Levels in Plasma and Brain of PD Animals
Plasma homocysteine levels in MPTP-treated mice and
MPTP+PPX-treated mice were not significantly different from
those of the control group. However, levodopa treatment
significantly increased plasma homocysteine levels in MPTP-
treated mice compared to the control group, MPTP-only, and
MPTP+PPX-treated mice (Fig. 6A). Moreover, levodopa admin-
istration significantly increased the levels of brain homocysteine in
MPTP-treated mice compared to that of the control, MPTP-only,
and MPTP+PPX-treated mice, whereas the concentration of brain
homocysteine was significantly reduced in the MPTP-only and
MPTP+PPX-treated mice compared to the controls (Fig. 6B). In
MPTP untreated mice, levodopa treatment or co-administration
of MK-801 and L-dopa in MPTP significantly increased plasma
and brain homocysteine levels compared to controls (Fig. S4 A).
Comparison of Neurogenic Activity Between Levodopa
and PPX in MTPT-treated PD Animals
NPCs in the SVZ were immunostained with BrdU to investigate
the effect of levodopa treatment on neurogenesis in vivo. The
immunohistochemical analysis revealed a significant decrease in
BrdU-positive cells in MPTP-treated mice compared to the
control animals; however, BrdU-positive cells were elevated in
the MPTP-mice treated with levodopa or PPX compared to the
MPTP-only mice (Fig. 7A). Most BrdU-positive cells in the SVZ
were co-localized with Ki-67, a proliferation marker in each
animal group (Fig. S4). Stereological analysis revealed that
decreased number of BrdU-positive cells in the SVZ of MPTP-
Neurogenesis in Parkinson’s Disease
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treated mice relative to the controls was more evident, and the
number of BrdU positive cells was much greater in the PPX-
treated mice than in the levodopa-treated mice (Fig. 7B).
Furthermore, levodopa treatment significantly decreased the
number of BrdU-positive cells in in MPTP untreated mice
compared to the control group (Fig. S5A), whereas co-adminis-
tration of MK-801 and L-dopa did not change neurogenic activity
in MPTP untreated mice (Fig. S5B).
Additionally, we analyzed whether MK-801 would lead to
modulate the decrease in levodopa treatment-associated neuro-
genesis. We found that MK-801 administration significantly
increased the number of BrdU-positive cells in the SVZ of
levodopa-treated PD mice (Fig. 7A and B). Meanwhile, MK-801
administration did not significantly change neurogenic activity in
the PPX-treated PD animals (Fig. 7A and B) or MPTP-only
treated mice (Fig. S6).
Discussion
This is the first study to evaluate the effect of levodopa-induced
hyperhomocysteinemia on neurogenesis in vitro and in vivo The
major findings were (1) elevated homocysteine by levodopa
treatment exerted an anti-proliferative effect on NPCs in the
SVZ, (2) levodopa-induced apoptosis in the NPCs is mediated by
Figure 1. Phenotype and proliferative capacity of cultured NPCs. NPCs isolated from the SVZ exhibited no GFAP-positive or OX-42-positive
cells (A and B). Most NPCs were immunostained with nestin (C and E), Ki67 (F and G), and MAP 2 (I and K). These marker-positive NPCs were visualized
using fluorescent secondary antibodies conjugated to DAPI (D, G, and J). Scale bar: 10 mm.
doi:10.1371/journal.pone.0050496.g001
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ERK signaling pathways possibly via the NMDA receptor, and (3)
the dopamine agonist produced a greater increase in neurogenesis
compare to levodopa.
Accumulating clinical evidence suggests that chronic adminis-
tration of levodopa in patients with PD lead to increase the
homocysteine synthesis. Our data showing that levodopa treat-
ment stimulated the release of homocysteine from cultured
astrocytes and increased homocysteine concentration in the
plasma and brain of MPTP-treated PD animals are consistent
with those findings. Unexpectedly, the level of brain homocysteine
in this study was significantly decreased in MPTP-treated mice
compared to controls. This may be ascribed to decreased basal
metabolism in catechol-O-methyltransferase (COMT)-mediated of
endogenous dopamine due to dopamine depletion and alterations
in methylation index by MPTP treatment [27–29]. Experimental
studies indicate that homocysteine acts as an excitatory amino-acid
by activating NMDA receptors [30]. Thus, homocysteine induces
mitochondrial dysfunction, free radicals and cytosolic calcium
accumulation, and activation of apoptotic pathways [13,31,32].
Accordingly, preclinical evidence has suggested that hyperhomo-
cysteinemia associated with levodopa treatment has a detrimental
effect on both dopaminergic and non-dopaminergic neurons in
PD models [33]. However, whether levodopa-induced hyperho-
mocysteinemia may contribute to accelerate the progression of
Figure 2. Expression of NMDA receptor subunits in NPCs. Immunocytochemistry revealed that the NPCs expressed NMDA receptor 2A and 2B
subunits (A and B). RT-PCR showed that NPCs expressed NMDA receptor 1, 2A, 2B, and C subunits (C). Scale bar: 20 mm.
doi:10.1371/journal.pone.0050496.g002
Figure 3. Levodopa-induced release of homocysteine from astrocytes. Levodopa treatment led to increase in extracellular concentration of
homocysteine in a time-dependent manner (A and B). Release of homocysteine by levodopa treatment was also dependent on the number of
astrocytes with the maximum level in the highest dose of levodopa. Homocysteine was not detectable in the astrocyte culture media after PPX
treatment (A and B). Homocysteine was detected by GC-mass. Values are means 6 SD (n = 4/group, *P,0.005).
doi:10.1371/journal.pone.0050496.g003
Neurogenesis in Parkinson’s Disease
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nigral motor dysfunction and the risk of extra nigral non-motor
features in patients with PD is controversial and remains to be
determined. In this regard, scientific evidence addressing the
metabolic consequences of levodopa treatment on other non-
dopaminergic systems, such as neurogenic system is critical for the
development of sophisticated therapeutic strategies for PD.
Our in vitro data demonstrated that the increase in homocys-
teine release in levodopa-treated astrocytes had a neurotoxic effect
on NPCs in the SVZ. Furthermore, the homocysteine-induced
phosphorylation of ERK via the NMDA receptors led to NPC
apoptosis. In accordance with previous studies [34,35], the NPCs
isolated from the SVZ in our study expressed NMDA receptor 2A-
C subunits as well as the NR1 subunit. The role of the NMDA
receptor in regulating an upstream MAPK superfamily and ERK-
mediated proapoptotic signals has been extensively investigated. In
NMDA receptor mediated neuronal toxicity, largely via the
NMDAR-mediated influx of extracellular Ca2+, ERK-MAP
kinase is known to be rapidly and transiently activated, and be
involved in glutamate-induced apoptosis [36,37]. Furthermore,
Poddar and Paul [14] demonstrated recently that elevated
homocysteine would lead to NMDA receptor-mediated neuronal
cell death through sustained activation of ERK-MAP kinase. Our
in vitro study supported these findings by showing that treatment
with a NMDA antagonist (MK-801) significantly attenuated
levodopa-induced activation of ERK signaling pathways and
apoptotic cell death in the NPCs. Accordingly, these data suggest
that elevated homocysteine by levodopa treatment has an
important role in antiproliferative effect on NPCs possibly through
NMDA receptor mediated the activation of ERK-dependent
proapoptotic pathways.
Figure 4. Levodopa treatment induced apoptotic cell death in NPCs. Levodopa treatment significantly increased caspase-3 activity in a time-
dependent manner in NPCs. Moreover, caspase-3 activity was significantly higher in the levodopa-treated NPCs than in the control or PPX-treated
NPCs at 72 h (A). The flow cytometric assays revealed that Annexin-V- positive cells increased significantly in the levodopa-treated NPCs compared to
the control and PPX-treated NPCs (B). The quantitative analysis revealed a significant increase in apoptotic cell death in the levodopa-treated NPCs
compared to the control or PPX-treated NPCs (C). NPC viability decreased significantly in levodopa-treated NPCs compared to that in the control and
PPX-treated NPCs (D). However, administration of MK-801 to the levodopa-treated NPCs significantly decreased caspase-3 activity, Annexin-V-positive
cells, and apoptotic cell death compared to those in the levodopa-only NPCs. On the other hand, MK-801 had no significant effect on apoptotic cell
death in PPX-treated NPCs (B-D). Values are means 6 SD (n = 4/group, *P,0.005).
doi:10.1371/journal.pone.0050496.g004
Neurogenesis in Parkinson’s Disease
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e50496
To evaluate the NMDA receptor modulation on SVZ
neurogenesis, we extended our study to an animal model of PD
using MPTP. As expected, neurogenesis in the SVZ as measured
by BrdU-positive cells was significantly reduced in the MPTP-
treated PD animals. This finding agrees with previous studies
reporting a relationship between dopamine depletion and
decreased neurogenesis in the SVZ in the postmortem brains of
patients with PD and animal models of PD [3,4]. Interestingly, our
in vivo data demonstrated that treatment with a NMDA
antagonist significantly increased neurogenesis in the SVZ of
levodopa-treated PD mice compared to that in levodopa-only PD
animals. Several lines of evidence have suggested that prolonged
NMDA receptor activation might decrease the rate of proliferation
and the number of newly generated neurons in the SVZ or dentate
gyrus [38,39]. However, the role of the NMDA receptor in
regulating neurogenesis is inconsistent and likely depends on the
NMDA receptor subtypes, aging, and exposure time or dose of
NMDA agonists/antagonists [2,40,41]. Thus, the NMDA antag-
onist may attenuate the prolonged NMDA receptor activation
produced by the levodopa-induced increase in homocysteine in the
brain, and in turn lead to decreased apoptosis of NPCs in the SVZ.
Our in vivo results further supports that elevated homocysteine by
levodopa treatment would modulate NMDA-dependent neuro-
genesis. However, contradictory results have been reported for the
NMDA subtypes underlying homocysteine-induced activation of
ERK2 and regulation of neurogenesis; the former is mediated
through NMDA 2A subunit and the latter is mediated via NMDA
2B subunit [14,38]. Further study is needed to clarify the signaling
pathways underlying homocysteine-mediated NMDA receptor
dependent regulation of neurogenesis.
Another interesting finding is comparative analysis of neuro-
genic activity between levodopa and dopamine agonists. Recent
studies have found that NPCs in the SVZ exhibited dopaminergic
receptors and dopaminergic innervation, suggesting that they are
important for the proliferation of NPCs in the SVZ. Importantly,
the neurogenic effects are mediated by activation of the D3
Figure 5. Effects of levodopa treatment on the regulation of ERK signaling. The phosphorylated form of ERK increased significantly in
levodopa-treated NPCs compared to that in the controls (A and B). MK-801 treatment in the levodopa-treated NPCs significantly attenuated the
expression of phosphorylated ERK compared to that of the levodopa-only NPCs (A and B). The expression of phosphorylated ERK did not change
significantly in PPX- treated NPCs compared to the controls. The results represent three replications in each group. *P,0.02.
doi:10.1371/journal.pone.0050496.g005
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Figure 6. Levodopa treatment led to increased levels of homocysteine in both plasma and brain Levodopa treatment in MPTP-
treated mice produced a significant increase in plasma (A) and brain (B) levels of homocysteine compared to that of the control,
MPTP-only, and MPTP+PPX- treated mice (A). Values are means 6 SE (n = 5; *P,0.05, **P,0.01).
doi:10.1371/journal.pone.0050496.g006
Figure 7. Comparison of neurogenic activity between levodopa and PPX in MTPT-treated PD animals. The immunohistochemistry
analysis revealed that the number of BrdU-positive cells decreased significantly in MPTP-treated mice compared to control mice, whereas levodopa or
PPX treatment increased BrdU-positive cells in MPTP-treated mice compared to MPTP-only treated mice (A). The stereological analysis revealed that
the number of BrdU positive cells was much greater in the PPX-treated mice than in the levodopa-treated mice (B). MK-801 administration
significantly increased the number of BrdU-positive cells in the SVZ of the levodopa-treated PD mice compared to the levodopa-only PD animals (A
and B), whereas no significant changes in neurogenic activity were observed in the PPX-treated PD animals following the administration of MK-801 (A
and B).Values are means 6 SD (n = 5, *P,0.02; **P,0.002). Scale bar: 20 mm.
doi:10.1371/journal.pone.0050496.g007
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dopamine receptors, whereby dopamine receptor activation
induces ciliary neurotrophic factor release into neurogenic niches
[42]. Adding to evidence that dopamine agonists augment
neurogenesis in animal models of PD [43], O’Sullivan et al. [44]
very recently demonstrated a positive impact of chronic levodopa
use on the number of neural stem cells in the SVZ of patients with
PD. To date, however, there are no available studies dealing with
a direct comparison of neurogenic activity between levodopa and
dopamine agonist in the same experimental design. In the present
study, we found that the number of cultured NPCs and BrdU-
positive cells in the SVZ of the PD animals was significantly higher
in PPX treatment group than in levodopa treatment group,
indicating that the neurogenic activity of the dopamine agonist
was superior to that of levodopa. The difference in neurogenic
activity may be the result of the detrimental effect of homocysteine
on NPCs by levodopa treatment. Moreover, as a member of the
D2 receptor family, PPX has a higher affinity for the D3 dopamine
receptor than dopamine [45], and this property may also
contribute to difference in neurogenic activities, being in favor of
dopamine agonist. Indeed, the number of BrdU-positive cells in
the SVZ was higher in the PD animals treated with levodopa than
in the PD mice that did not receive levodopa treatment. This
finding may suggest that the pro-neurogenic effect of dopaminer-
gic receptor stimulation by levodopa is stronger than the anti-
neurogenic effect resulted from levodopa-induced hyperhomocys-
teinemia; however, further clinical evidence of postmortem study
regarding the role of dopamine agonist in modulation of
neurogenesis may clarify this issue.
Regarding the functional impact of adult neurogenesis, several
lines of evidence have suggested that adult neurogenesis plays a
regulatory role in olfaction, mood, and memory. In the PD animal
model, Van Kampen and Eckman [6] reported that an increase in
neurogenesis following treatment with a dopaminergic drug
restored the nigrostriatal dopaminergic projection concomitant
with function motor recovery, even though a debate exists as to
whether NPCs from the SVZ would transdifferentiate into nigral
dopaminergic phenotypes or migrate into the striatum and then
incorporate into host neurons [46]. From a therapeutic perspec-
tive, the modulation of endogenous adult neurogenesis to repair
the damaged PD brain would have a significant impact in future
strategy of PD treatment. Furthermore, the neurogenic activity of
the dopaminergic drugs commonly used to treat patients with PD
must be a consideration for clinical practice along with neuro-
protection, dopaminergic medication-associated motor complica-
tions, and dyskinesia. In this regard, our finding that dopamine
agonists have greater neurogenic activity than levodopa is
clinically relevant for human PD treatment. Future studies are
needed to determine whether inhibition of homocysteine synthesis
using clinically available COMT inhibitor can protect NPCs
against levodopa-induced hyperhomocysteinemia.
In summary, the present study demonstrated that a levodopa-
induced increased in homocysteine has a detrimental effect on
adult neurogenesis via NMDA receptor-mediated ERK signaling
pathways, and modulation of levodopa-induced hyperhomocys-
teinemia by a NMDA antagonist or dopaminergic agonist is
clinically relevant for human PD treatment in terms of adult
neurogenesis. Future studies focusing on the modulation of adult
neurogenesis using small molecule receptor agonists would extend
the clinical applications of our findings.
Supporting Information
Figure S1 In vivo study design. At 6 weeks of age, the mice
received subchronic injections of MPTP freshly dissolved in
normal saline (25 mg/kg/day as the free base in normal saline by
intraperitoneal injection (i.p). On day 28 after the first adminis-
tration of levodopa, PPX, or normal saline, all animals were
assigned to a BrdU injection. BrdU was administered i.p once
daily on five subsequent days.
(DOC)
Figure S2 The viability of astrocytes and NPCs. The
astrocytes were treated with different doses of levodopa (A),
pramipexol (B), and MK-801 (C) to identify a dose that did not
induce cell death. Values are means 6 SD (n= 3/group,
*P,0.005).
(DOC)
Figure S3 The direct effects of homocysteine(Hcy) on
the NPCs. The NPCs were treated with varying doses of
homocysteine in 72 hrs to determine the direct effects of
homocysteine on the viability of NPCs. Homocysteine treatment
decreased the viability of NPCs in a dose-dependent manner (A).
Western blot analysis revealed that homocysteine treatment
increased the expression of phosphorylated ERK in a dose-
dependent manner (B) and the expression of phosphorylated ERK
was decreased in presence NMDA antagonist, MK-801 (C). The
treatment of SCH-23390, a D1 receptor antagonist, did not
decrease the expression of phosphorylated ERK (D), which suggest
that ERK activation is not mediated via D1 receptor. Values are
means 6 SD (n= 3/group, *P,0.05, **P,0.01).
(DOC)
Figure S4 Double immunochemical analysis of BrdU
antibody and Ki-67 antibody in each animal group. The
immunohistochemical analysis revealed that most BrdU-positive
cells in the subventricular zone (SVZ) were co-localized with Ki-67
in control, MPTP-only treated, MPTP and levodopa treated,
MPTP and PPX treated groups. The number of Ki-67-positive
cells in the SVZ in each animal group did not differ significantly
compared with BrdU-positive cells.
(DOC)
Figure S5 The effects of levodopa treatment on the level
of homocysteine and neurogenesis in MPTP untreated
mice. Levodopa treatment or co-administration of MK-801 and
L-dopa in MPTP untreated mice led to increase in both plasma
and brain homocysteine levels compared to the control (A).
Immunohistochemical analysis revealed that levodopa treatment
significantly decreased the number of BrdU-positive cells in in
MPTP untreated mice compared to the control group, whereas
co-administration of MK-801 and levodopa did not change
neurogenetic activity in MPTP untreated mice compared to
controls (B). And Values are means 6 SE (n = 4; *P,0.05,
**P,0.01).
(DOC)
Figure S6 The modulatory effect of NMDA activation
solely induced by MTPT treatment on neurogenic
activity. Immunohistochemical (A) and stereological (B) analyses
revealed that the number of BrdU-positive cells in MPTP-only
treated mice not differ significantly compared with those in MPTP
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